AbbVie Inc. (ABBV)
| Market Cap | 293.06B |
| Revenue (ttm) | 54.40B |
| Net Income (ttm) | 5.99B |
| Shares Out | 1.77B |
| EPS (ttm) | 3.37 |
| PE Ratio | 49.25 |
| Forward PE | 13.96 |
| Dividend | $6.20 (3.74%) |
| Ex-Dividend Date | Jul 15, 2024 |
| Volume | 4,108,039 |
| Open | 168.63 |
| Previous Close | 170.37 |
| Day's Range | 165.45 - 168.76 |
| 52-Week Range | 132.70 - 182.89 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 185.00 (+11.47%) |
| Earnings Date | Jul 25, 2024 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]
Financial Performance
In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.86 billion, a decrease of -58.91%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ABBV stock is "Strong Buy." The 12-month stock price forecast is $185.0, which is an increase of 11.47% from the latest price.
News
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
NORTH CHICAGO, Ill., July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens.
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive Chairman Robert A.
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicu...
AbbVie Acquires Celsius Therapeutics
Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. , June 27...
Introducing Allē Payment Plans, Powered by Cherry
Allē Members Enjoy the Aesthetic Treatments They Love Today, and Pay Over-Time with No Hard Credit Checks Participation Comes at No Cost* to Aesthetic Providers for Allergan Aesthetics Treatments and ...
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
- EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL)- Bispec...
US FDA declines to approve AbbVie's Parkinson's disease therapy
AbbVie said on Tuesday the U.S. Food and Drug Administration has rejected the company's marketing application for its therapy to treat motor fluctuations in adults with advanced Parkinson's disease.
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's third-party manufac...
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , June 21, 2024 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.55 per share.
AbbVie stock price forecast: $200 on the cards?
On June 20, 2024, AbbVie Inc. (NYSE:ABBV) announced that it has received FDA approval for expanding the use of its interleukin-23 (IL-23) inhibitor, Skyrizi, to treat adults with moderate to severe ul...
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
Ms. Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director NORTH CHICAGO, Ill.
AbbVie says FDA approves Skyrizi for ulcerative colitis
Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with moderate to severe forms of ulcerative colitis, broadening the company's arsenal o...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance stu...
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
NORTH CHICAGO, Ill. , June 14, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 28, 2024, to purchase...
Final Trades: Nvidia, Abbvie, ConocoPhillips and Vertex Pharma
The Investment Committee share their top stocks to watch for the second half.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbV...
AbbVie inks immune disorder drug licensing deal with China's FutureGen
U.S. drugmaker AbbVie will develop and commercialize an experimental treatment for inflammatory bowel disease (IBD) from China's FutureGen Biopharmaceutical under a licensing agreement, the companies ...
AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
- Global license agreement to focus on the development of FG-M701, a TL1A antibody, for the treatment of inflammatory bowel disease (IBD) NORTH CHICAGO, Ill. and BEIJING , June 13, 2024 /PRNewswire/...
US Gastroenterologists Express Anticipation for Approval of AbbVie's Skyrizi in Ulcerative Colitis, Projecting Rapid Adoption Post-Launch
Despite enthusiasm for Skyrizi, key updates for various developmental assets in ulcerative colitis were released at Digestive Disease Week, holding the potential to impact sentiments. Despite enthusia...
BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients
For The Second Year, 20 Women Entrepreneurs Will Each Receive $25,000 In Funding, Plus Access to Mentorship and Community—Helping to Close the Confidence Gap IRVINE, Calif. , June 11, 2024 /PRNewswire...
Focus: AbbVie's tight grip on Humira market raises concerns about biosimilars
AbbVie's top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for pr...
Final Trades: Amazon, Goldman Sachs, AbbVie and IQVIA Holdings
The Investment Committee give you their top stocks to watch for the second half.
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
AbbVie said on Thursday its therapy to treat patients with a type of ovarian cancer has met the main goal of a mid-stage trial.
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
PICCOLO trial met its primary endpoint of objective response rate (ORR) Data from the study will be presented at a future medical meeting NORTH CHICAGO, Ill. , June 6, 2024 /PRNewswire/ -- AbbVie (NYS...
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
Allē Members Can Celebrate with Double Points and Enter for a Chance to Win $5,000 IRVINE, Calif. , June 6, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the makers of BOTO...